Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Last trade$3.41
Day change-$0.25 (-6.83%)
Day range$3.37 – $3.76
Volume98,822
Market cap$53M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$52.7M
Price / earnings
—
Price / book
-3.56×
Price / sales
221.45×
EV / sales
260.63×
EV / EBITDA
-3.13×
Profitability
Earnings per share
-$1.86
Return on assets
-121.07%
Return on equity
181.16%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.3×
Current ratio
0.85×
Quick ratio
0.84×
Cash ratio
0.58×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.61M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CLNN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$56K
$90K
$15K
$77K
$15K
$27K
$81K
$91K
Cost of revenue
$16K
$36K
$0
$23K
$0
$0
$20K
$18K
Gross profit
$40K
$54K
$15K
$54K
$15K
$27K
$61K
$73K
Selling, general and administrative
$1.94M
$1.93M
$1.75M
$2.05M
$2.15M
$2.38M
$2.66M
$3.16M
Research and development
$4.45M
$3.47M
$329K
$5.5M
$3.51M
$3.51M
$1.48M
$5.57M
Total operating expenses
$6.39M
$5.4M
$2.08M
$7.55M
$5.66M
$5.89M
$4.14M
$8.73M
Operating income
-$6.35M
-$5.35M
-$2.06M
-$7.5M
-$5.65M
-$5.86M
-$4.08M
-$8.66M
Interest expense
-$665K
-$695K
-$791K
-$746K
-$649K
-$679K
-$608K
-$516K
Income before taxes
$3.92M
-$13.42M
-$8.09M
-$9.23M
-$8.78M
-$7.42M
-$751K
-$13.55M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$3.92M
-$13.42M
-$8.09M
-$9.23M
-$8.78M
-$7.42M
-$751K
-$13.55M
Net income attributable to common shareholders
$3.92M
-$13.42M
-$8.09M
-$9.23M
-$8.78M
-$7.42M
-$751K
-$13.55M
EBITDA
-$6M
-$4.99M
-$1.71M
-$7.14M
-$5.28M
-$5.5M
-$3.67M
-$8.25M
Basic earnings per share
$0.30
-$1.08
-$0.69
-$0.85
-$0.85
-$0.78
-$0.09
-$1.61
Diluted earnings per share
$0.05
-$1.08
-$0.69
-$0.85
-$0.85
-$0.78
-$0.09
-$1.61
Recent news
Company coverage with links to the original publishers.
Clene Inc. (CLNN) reported quarterly earnings of $0.05 per share, beating consensus estimates of a $0.46 loss, representing a +110.87% earnings surprise. However, the company missed revenue expectations with $0.06 million versus the consensus estimate, down 37.78%. The stock has underperformed the market by 35.8% year-to-date and carries a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Clene Inc. (Nasdaq: CLNN) announced the submission of a New Drug Application (NDA) to the FDA in October 2026 seeking accelerated approval of CNM-Au8 for treating amyotrophic lateral sclerosis (ALS). The submission is based on neurofilament light chain biomarker data and clinical outcomes. The company plans to continue with a confirmatory Phase 3 RESTORE-ALS study while awaiting FDA review.
Clene Inc. announced key 2026 milestones for its investigational ALS drug CNM-Au8, including an FDA Type C meeting by Q1 2026, NDA submission via accelerated pathway in Q2 2026, and potential PDUFA date in H2 2026. The company secured $28 million in funding with runway into Q4 2026, and plans to initiate a Phase 3 confirmatory trial later in 2026. CNM-Au8 has demonstrated prolonged survival benefits and favorable safety profile across over 800 treated ALS patients.
Clene Inc. will host an investor call and webcast on December 3, 2025, to provide an update on its CNM-Au8 program for treating amyotrophic lateral sclerosis (ALS). The company is a late clinical-stage biopharmaceutical firm focused on neurodegenerative disease treatments.
Clene, a clinical-stage biopharmaceutical company, reported a net loss of $(0.78) per share in Q2 2025, with minimal revenue of $27,000. The company continues advancing its CNM-Au8 therapy for neurodegenerative diseases while managing tight cash resources.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.